InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
2024年5月16日 - 9:30AM
ビジネスワイヤ(英語)
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading
biopharmaceutical company focusing on the treatment of cancer and
autoimmune diseases, today announced the completion of patient
enrollment for the phase II clinical trial of ICP-488, a TYK2
(tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of
psoriasis.
This is a multicenter, randomized, double-blind,
placebo-controlled phase II clinical study aimed at evaluating the
efficacy, safety, PK and PD characteristics of ICP-488 in Chinese
adult patients with moderate to severe plaque psoriasis. A total of
129 patients were enrolled in this study. Patients were randomly
assigned to one of three treatment groups in a 1:1:1 ratio, a 6mg
once-daily group, a 9mg once-daily group, and a placebo group, for
12 consecutive weeks of treatment.
ICP-488 is an oral, potent and selective TYK2 allosteric
inhibitor. By binding the JH2 domain, ICP-488 blocks the signal
transduction of IL-23, IL-12, type 1 IFN and other inflammatory
cytokine, thereby inhibiting the pathological process of autoimmune
and inflammatory diseases. ICP-488 has demonstrated good efficacy
and safety in the phase I study of treating psoriasis patients.
Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare
said, “Psoriasis requires long-term management, and there is still
a significant unmet demand for new drugs, especially oral
medications in its treatment. We are very pleased to see the
completion of patient enrollment in the phase II clinical trial for
the treatment of psoriasis with ICP-488. We remain committed to
diligently advancing the clinical development of this promising
therapy, with the goal of providing improved treatment options to
psoriasis patients as soon as possible.
Recent data indicates that approximately seven million people in
China are currently living with psoriasis1, and this number is on
the rise2. Existing treatment options do not fully address the
needs of those affected by this condition, highlighting a
significant gap in available therapies. There is a particularly
acute demand for new, oral medications. Many patients, especially
those with moderate-to-severe psoriasis, continue to be
persistently undertreated or remain untreated altogether3.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company
committed to discovering, developing, and commercializing
first-in-class and/or best-in-class drugs for the treatment of
cancer and autoimmune diseases with unmet medical needs in China
and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai,
Guangzhou, Hong Kong, and United States.
_______________________ 1 Epidemiological Investigation on
Psoriasis 2 2021. Progress in Epidemiological Investigation of
Psoriasis, Journal of Diagnostics Concepts & Practice. 2021. 3
Chinese Guidelines for the Diagnosis and Treatment of Psoriasis
(2018). Chinese Journal of Dermatology. 2019. Research on the
Situation of Psoriasis Healthcare in China based on the Global
Monitoring Project of Psoriasis and the Causal Relationship between
Psoriasis and Obesity and Type II Diabetes. 2020
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515515165/en/
Media Chunhua Lu 86-10-66609879
chunhua.lu@innocarepharma.com
Investors 86-10-66609999 ir@innocarepharma.com